Angiomax Monotherapy Associated with Reduced Net Adverse Clinical Events, Major Bleeding and Cardiac Related Death Compared to Heparin Plus a Glycoprotein IIb/IIIa Inhibition in Primary PCI: Results of HORIZONS AMI

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.